Administration of ondansetron is associated with lethal outcome

Pediatrics. 2010 Jun;125(6):e1514-7. doi: 10.1542/peds.2009-2795. Epub 2010 May 3.

Abstract

We report here the case of a child with a known muscular abnormality and susceptibility to malignant hyperthermia who abruptly died after receiving a therapeutic dose of ondansetron. Also, we discuss the pharmacodynamic relationship of ondansetron to malignant hyperthermia in a susceptible host.

Publication types

  • Case Reports

MeSH terms

  • Antiemetics / adverse effects*
  • Antiemetics / pharmacology
  • Antiemetics / therapeutic use
  • Child, Preschool
  • Diseases in Twins / genetics
  • Fatal Outcome
  • Genetic Predisposition to Disease*
  • Humans
  • Male
  • Malignant Hyperthermia / etiology*
  • Malignant Hyperthermia / genetics
  • Myopathies, Structural, Congenital / genetics*
  • Ondansetron / adverse effects*
  • Ondansetron / pharmacology
  • Ondansetron / therapeutic use
  • Ryanodine Receptor Calcium Release Channel / genetics*
  • Triplets
  • Twins, Monozygotic
  • Vomiting / drug therapy

Substances

  • Antiemetics
  • Ryanodine Receptor Calcium Release Channel
  • Ondansetron